Regen Biopharma corrects convertible debt date, becomes current on SEC filings, plans to settle notes

Regen BioPharma Inc

Corrects earlier statement: no convertible debt issued since July 2019, not July 2020.
Company is no longer delinquent in SEC reporting as of August 27, 2021 10-Q filing.
Intends to negotiate settlement of remaining convertible notes to reduce or eliminate dilution, no assurance given.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.